All Releases All Releases MAR Regulatory Releases Selected Company Releases News Category All All Releases MAR Regulatory Releases Selected Company Releases Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 Nov 16, 2026 Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses Nov 13, 2026 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Nov 9, 2026 Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline Nov 3, 2026 Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts Nov 2, 2026 Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation Oct 29, 2026 Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit Oct 22, 2026 Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis Oct 20, 2026 Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting Oct 19, 2026 Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease Oct 8, 2026 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities